Which factor increases the risk of hepatotoxicity with acetaminophen?

Which factor increases the risk of hepatotoxicity with acetaminophen?

• A. Using only short-term, low-dose therapy.
• B. Concurrent alcohol use and preexisting liver disease.
• C. Taking with meals to reduce absorption.
• D. Using non-prescription analgesics only.

Answer: (B)

The risk for acetaminophen hepatotoxicity rises when the liver’s ability to detoxify a toxic metabolite is compromised or when more of that metabolite is produced. Normally, acetaminophen is processed safely, but a portion is converted by liver enzymes into NAPQI, a harmful substance. The body neutralizes NAPQI by using glutathione. If glutathione stores are depleted or more NAPQI is formed, liver cells can be damaged. Alcohol use, especially chronic drinking, increases the activity of the enzyme system (CYP2E1) that makes NAPQI, leading to more of this toxic metabolite. At the same time, alcohol can deplete liver glutathione, reducing the capacity to detoxify NAPQI. Preexisting liver disease further limits the liver’s ability to cope with additional toxin exposure. Put together, concurrent alcohol use and existing liver disease markedly raise the risk of acetaminophen-related liver injury. Taking acetaminophen for a short period at low doses and with meals to slow absorption does not introduce the same elevated risk as having alcohol use plus liver disease. Non-prescription analgesic use alone doesn’t inherently increase hepatotoxic risk unless it leads to higher cumulative exposure or interacts with liver function, which is why the combined factors described are the key risk.

The risk for acetaminophen hepatotoxicity rises when the liver’s ability to detoxify a toxic metabolite is compromised or when more of that metabolite is produced. Normally, acetaminophen is processed safely, but a portion is converted by liver enzymes into NAPQI, a harmful substance. The body neutralizes NAPQI by using glutathione. If glutathione stores are depleted or more NAPQI is formed, liver cells can be damaged.

Alcohol use, especially chronic drinking, increases the activity of the enzyme system (CYP2E1) that makes NAPQI, leading to more of this toxic metabolite. At the same time, alcohol can deplete liver glutathione, reducing the capacity to detoxify NAPQI. Preexisting liver disease further limits the liver’s ability to cope with additional toxin exposure. Put together, concurrent alcohol use and existing liver disease markedly raise the risk of acetaminophen-related liver injury.

Taking acetaminophen for a short period at low doses and with meals to slow absorption does not introduce the same elevated risk as having alcohol use plus liver disease. Non-prescription analgesic use alone doesn’t inherently increase hepatotoxic risk unless it leads to higher cumulative exposure or interacts with liver function, which is why the combined factors described are the key risk.